Allison Gatlin

Allison Gatlin is a financial journalist who specializes in covering biotech and pharmaceutical companies. She is known for her unbiased reporting and thorough analysis. Her work is often characterized by its clarity and readability.

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

AbbVie Raises Profit Forecast Following Strong Q3 Performance

Broke On: Saturday, 28 October 2023 AbbVie has raised its profit forecast for 2023 following a strong Q3 performance. The company reported non-GAAP EPS of $2.95 and revenue of $13.93 billion for the quarter, beating estimates. AbbVie's flagship drug, Humira, continues to be a significant contributor to the company's revenue. The company has increased its quarterly dividend by 10%.